Subject: Subcontract Agreement between the University of Michigan and Eleven Therapeutics Corporation

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the UMOR Conflict of Interest Review Committee. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Committee and agreed to by the parties involved.

This proposed agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Dr. Andrew Alt is an employee of the University of Michigan (“University”), and a partial owner of Eleven Therapeutics Corporation. The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Dr. Andrew Alt, the Director of the Center for Chemical Genomics at the Life Sciences Institute, is the partial owner of a for-profit company called Eleven Therapeutics Corporation (the “Company”). The Company wishes to fund an NIH (prime) project entitled “Optimization of enkephalin amplifiers as novel, safe, non-addictive analgesics to prevent opioid use disorder” (ORSP #19-PAF08396) in the Life Sciences Institute under the direction of Dr. Andrew Alt. The purpose of this project is to chemically optimize prototype enkephalin amplifier molecules as novel, effective, and safe analgesics to replace oxycodone and related opioid drugs.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $2,466,504. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreement will support an effort by Dr. Alt to use his expertise and University laboratory, as well as other University resources, to chemically optimize prototype enkephalin amplifier molecules as novel, effective, and safe analgesics to replace oxycodone and related opioid drugs.
Recommendations:

This matter has been reviewed and approved by the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with Eleven Therapeutics Corporation.

Respectfully submitted,

Rebecca Cunningham
Interim Vice President for Research
September 2019